Phase I, dose-escalation, trial will investigate the tolerability of PRX 302 in men with symptomatic, mild to moderate, benign prostatic hyperplasia

Trial Profile

Phase I, dose-escalation, trial will investigate the tolerability of PRX 302 in men with symptomatic, mild to moderate, benign prostatic hyperplasia

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2010

At a glance

  • Drugs Topsalysin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Dec 2010 According to a Protox Therapeutics media release, results of this trial plus another phase II trial [see 700028763] have been published online in European Urology.
    • 08 Oct 2008 Positive 12-month results have been reported in a Protox Therapeutics media release.
    • 20 May 2008 Preliminary results will be presented at the 2008 AUA meeting on 21 May 2008, according to a Protox Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top